Drug manufacturer Pfizer reported a quarterly revenue for the third quarter of $12.09 billion, falling by 2% compared to its corresponding quarter, last fiscal. However, it beat analysts' estimates of $11.56 billion as sales of its pneumonia vaccine and breast cancer drug Ibrance rose. The company's reported net income fell to $2.13 billion from $2.67 billion last year. 